Keywords:
Cancer, Diagnostic procedure, Contrast agent-intravenous, MR, Contrast agents, Breast
Authors:
M. Hansen, S. Bäckström, L. Egeblad, A. Olsson, T. Sivik Sonne, O. Axelsson; Lund/SE
DOI:
10.26044/ecr2019/C-2061
References
[1] Eliana Gianolio,
Sania Bäckström,
Rodrigo M Petoral Jr,
Anders Olsson,
Silvio Aime,
Oskar Axelsson (2018).
Manganese-based Nanoparticles as high relaxivity MRI contrast agent.
Manuscript accepted for publication in 'European Journal of Inorganic Chemistry',
doi: 10.1002/ejic.201801472
[2] Eriksson P-O,
Aaltonen E,
Petoral R Jr,
Lauritzson P,
Miyazaki H,
et al.
(2014) Novel Nano-Sized MR Contrast Agent Mediates Strong Tumour Contrast Enhancement in an Oncogene-Driven Breast Cancer Model.
PLoS ONE 9(10): e107762.
doi:10.1371/journal.pone.0107762
[3] Pulaski BA and Ostrand-Rosenberg S (2001) Mouse 4T1 breast tumour model.
Curr Protoc Immunol.
Chapter 20: Unit 20.2.
[4] Rohrer M,
Bauer H,
Mintorovitch J,
Requardt M,
Weinmann H-J (2005) Comparison of magnetic properties of MRI contrast media solutions at different magnetic field strengths.
Invest Radiol 40: 715–724.
[5] Avila DS,
Puntel RL,
Aschner M (2013) Manganese in Health and Disease.
Met Ions Life Sci.
13:199–227.